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Antiretroviral drugsAmyloid ﬁbrils play important roles in HIV-1 infection. We found peptides derived from the HIV-1
gp120 co-receptor binding region, which are deﬁned as enhancing peptides (EPs), could form
amyloid ﬁbrils and remarkably enhance HIV-1 infection. EPs bound to the virus and promoted
the interaction between HIV-1 and target cells. The antiviral efﬁcacy of antiretroviral drugs (ARVs)
was substantially impaired in the presence of EPs. Epigallocatechin gallate (EGCG) could both inhibit
the formation of ﬁbrils composed of EPs and counteract the EP-mediated enhancement of HIV-1
infection. Our ﬁndings identify viral derived amyloid ﬁbrils that hold potential for biochemical
applications.
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 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction peptides individually could form amyloid ﬁbrils that drasticallyEarly in our exploration of the mechanism of anti-HIV activity
of T-20, we found that peptides 6312 and 6313 derived from the
HIV-1 gp120 co-receptor binding region could signiﬁcantly
abrogate T-20-mediated inhibition of HIV-1 infection [1]. Thus,
we speculated that T-20 might interact with the HIV-1 co-receptor
binding region of gp120 as its potential mechanism of action.
However, no direct interaction between T-20 and either peptide
6312 or 6313 was detected in vitro. Interestingly, these twoenhanced HIV-1 infection. These amyloid-forming peptides were
deﬁned as enhancing peptides (EPs).
Amyloid ﬁbrils are critical aetiologies of several neurodegener-
ative diseases and systemic amyloidoses because they induce
abnormal accumulation of protein or peptide aggregates [2]. In
addition, amyloid ﬁbrils play an important role in microbial
infection [3,4] . For example, some bacteria and fungi can employ
amyloid ﬁbrils to enhance their virulence and to invade the host
[5–7]. Recent studies have shown that HIV-1 might also utilise
amyloid ﬁbrils to promote viral entry. Beta-amyloid ﬁbrils, the
pathogenic agent of Alzheimer’s disease, could enhance HIV-1
infection at the stage of virus attachment [8]. Peptides derived
from prostatic acidic phosphatase (PAP, predominant component
PAP248–286) in semen, designated as semen-derived enhancer of
viral infection (SEVI), signiﬁcantly enhanced HIV-1 infection via
1516 S. Tan et al. / FEBS Letters 588 (2014) 1515–1522the formation of amyloid ﬁbrils. Aside from PAP, peptides derived
from physiologically cleaved coagulum proteins in semen could
also form amyloid ﬁbrils to enhance HIV-1 infection [9]. Most of
the amyloid ﬁbrils reported thus far originate from the host
environment. Limited investigation has been performed to exam-
ine whether some viral protein-derived amyloid ﬁbrils might exert
an effect on HIV-1 infection or pathogenesis.
In this study, we investigated the ability of EPs to form amyloid
ﬁbrils and, in turn, to enhance HIV-1 infectivity. Interestingly, EPs
exhibit a strong tendency to form amyloid ﬁbrils in vitro, which can
remarkably enhance HIV-1 infection by promoting the interaction
between viruses and cells. Signiﬁcantly, the antiviral efﬁcacies of a
panel of antiretroviral drugs (ARVs) are impaired in the presence of
EPs. The addition of epigallocatechin gallate (EGCG), which has
been shown to inhibit amyloid ﬁbrillogenesis and to disrupt amy-
loid ﬁbrils derived from several proteins [10,11], also displayed
similar effects on EP-derived ﬁbrils. Based on our results, the po-
tential roles of EPs in viral pathogenesis and their biochemical
applications are discussed.
2. Materials and methods
2.1. Reagents and cells
MT-2 cells, TZM-bl cells, primary HIV-1 strains, the anti-p24
monoclonal antibody (183-12H-5C), antiviral compounds and
HIV-1 clinical isolates were obtained from the National Institutes
of Health AIDS Research and Reference Reagent Program. CEMx
174 5.25M7 cells were kindly provided by C. Cheng–Mayer. Thio-
ﬂavin T (ThT), Congo red and EGCG were purchased from Sigma
(St. Louis, MO). The plasmids of CXCR4-tropic NL4-3, CCR5-tropic
92TH014.12 and dual-tropic 81A and NL4-3 infectious clones were
gifts from Jan Münch of Ulm University, Germany.
2.2. Peptide synthesis and ﬁbril formation
Various EPs, including EP1, EP2, EP3 and scrEP1, were
synthesised with purities above 90% by Huada Biotech Company
(Shanghai, China). Lyophilised peptides were dissolved in DMSO
at a concentration of 10 mg/ml as stock solutions. Aliquots were
stored at 20 C. The peptides were diluted in PBS at various concen-
trations before use. PAP248–286 (SEVI) [12] was synthesised by GL
Biochem (Shanghai, China). This lyophilised peptide (>95% purity)
was dissolved in PBS at a concentration of 10 mg/ml. Formation of
SEVI ﬁbrils was promoted via agitation at 37 C for 2–10 days at
1200 rpm using an Eppendorf Mixmate.
2.3. Detection of amyloid ﬁbrils
Amyloid ﬁbril formation was monitored using ThT and Congo
red [13]. Brieﬂy, peptides at 25 lM were added to 50 lM ThT.
The ﬂuorescence intensity was then measured. For the time-re-
solved ThT assay, 500 lM EP2 was incubated with different
concentrations of EGCG at 37 C. At the indicated time points,
5 ll aliquots were removed and mixed with 95 ll of 50 lM ThT
solution, and the ﬂuorescence intensity was measured. The struc-
ture of ﬁbrils were visualised using a Tecnai 12 (Philips/FEI, USA)
transmission electron microscope as described previously (12).
2.4. Virus production
CXCR4-tropic NL4-3, CCR5-tropic 92TH014.12 and dual-tropic
81A and NL4-3 infectious HIV-1 clones were prepared as
previously described [14]. The p24 antigen concentration was
determined via ELISA, as previously described [15].2.5. Virus infectivity assay
The enhancing effects of EPs on HIV-1 infectivity (both infec-
tious clones and clinical isolates) were determined using TZM-bl
cells [12]. To study the counteracting effect of EGCG on EP2-med-
iated enhancement of HIV-1 infection, EP2 was ﬁrst incubated with
EGCG at 37 C for 48 h under constant agitation. The mixtures were
then centrifuged at 5000 rpm for 15 min. The pellets were dis-
solved in medium and incubated with R5-tropic virus. Then, the
mixtures were used to infect TZM-bl cells.
To assess the EP-induced promotion of cell–cell HIV-1 transmis-
sion, HIV-1BaL-infected PBMCs [16] were mixed with peptide for
10 min at 37 C. Then, the mixtures were added to CEMx174
5.25M7 cells and cultured at 37 C for 3 h. The cells were then cen-
trifuged and cultured for 3 days. The cells were collected and lysed
for analysis of luciferase activity.
The inhibitory activity of ARVs in the presence of 2 lM EP2 was
determined as previously described [17,18].
2.6. Virus removal assay
EPs were incubated with R5-tropic viruses at room temperature
for 5 min. Subsequently, the mixture was added to the cells. After
3 h, cells were washed and replaced with fresh medium. The lucif-
erase activity was measured 72 h later. Alternatively, the R5-tropic
viruses were ﬁrst added to the cells. After a 3-h binding period, the
unbound virus was removed and fresh medium with or without
peptides was added. Luciferase activity was determined 72 h later.
2.7. Virus pull-down assay
The binding of HIV-1 to the EPs was determined using a virus
pull-down assay [14]. Brieﬂy, the peptides at graded concentra-
tions were mixed with the R5-tropic virus (100 ng/ml p24) for
1 h at 37 C, followed by centrifugation at 5000 rpm for 5 min to
pellet the ﬁbrils and the bound virions. The proportion of p24
and the infectivity of the HIV-1 bound to the pellet were evaluated.
2.8. Cell binding assay
Graded dilutions of EPs were ﬁrst incubated with TZM-bl cells at
37 C for 1 h. Then, the unbound peptides were washed once with
medium. The R5-tropic virus (100 ng/ml) was incubated with the
cells at 37 C for 1 h, followed by washing the cells once with med-
ium. Then, the cells were either lysed in 5% Triton X-100 tomeasure
p24 levels or cultured for 72 h to assay the luciferase activity.
3. Results
3.1. EPs form amyloid ﬁbrils and enhance the infectivity of HIV-1
infectious clones
EPs were derived from HIV-1 MN gp120 co-receptor binding re-
gion. EP1 and EP2 are 15-amino acids in length, with an 11-amino
acid overlap between the two peptides. EP3 covers the length of
EP1 and EP2 (Fig. 1A). All of the EPs could signiﬁcantly enhance
the infectivity of the R5-tropic, X4-tropic and dual-tropic HIV-1
infectious clones in TZM-bl cells (Fig. 1B, C and D). When applied
at the same concentration, both EP1 and EP3 exhibited a more pro-
nounced increase in HIV-1 infection than SEVI, the positive control.
EP3 boosted HIV-1 infection more potently than EP1 or EP2. The
scrambled sequence of EP1 displayed no ability to enhance HIV-1
infection (Fig. 1B, C and D). Cytotoxicity assay demonstrated that
EPs at 40 lM displayed no cytotoxicity to the target cells (data
not shown).
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Fig. 1. EPs remarkably enhance the infectivity of HIV-1 clones. (A) Amino acid sequences of EPs, the scrambled sequence of EP1 and PAP248–286. EPs are derived from HIV-1
MN gp120. The numbers correspond to the amino acid positions of gp120. (B–D) Enhancement of HIV-1 infectivity by EPs. TZM-bl cells were infected with CCR5-tropic
92TH014.12 virions (30 ng/ml p24, B), CXCR4-tropic NL4-3 virions (70 ng/ml p24, C) or dual-tropic 81A and NL4-3 virions (150 ng/ml p24, D) in the presence of a graded
concentration of EPs. After a 3-day infection period, the infectivity was determined via the measurement of luciferase activity. Results are presented the means and standard
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speculated that EPs might form amyloid ﬁbrils that were water
insoluble. As shown in Fig. 2, EPs could bind to the amyloid-speciﬁc
dyes Congo red and ThT in a dose-dependent manner (Fig. 2A and
B). Notably, unlike SEVI, which ﬁbril formation requires speciﬁc
conditions, including agitation, a suitable salt concentration and
pH of the solution [19], EPs could spontaneously form amyloid ﬁ-
brils. Next, we performed transmission microscopy to examine
the morphology of amyloid ﬁbrils composed of EPs. Interestingly,
the amyloid ﬁbril structures of EPs are different from that of SEVI
(Fig. 2C). EPs form short and soft amyloid-like ﬁbrils, while SEVI
forms long and rigid amyloid ﬁbrils. Next, we conﬁrmed that the
ultrastructure of the amyloid ﬁbrils corresponded to the enhance-
ment of HIV-1 infectivity. After centrifugation of the EP solution,
the supernatants, containing soluble peptides, did not enhance
HIV-1 infectivity, while the pellet, containing amyloid ﬁbril aggre-
gates, did enhance HIV-1 infectivity (Fig. 2D).3.2. EPs enhance the infection of various HIV-1 clinical isolates and
cell-associated HIV-1
Subsequently, we tested the potential enhancing effect of EPs
on different primary HIV-1 isolates. As shown in Fig. 3A–D, EPs
substantially enhanced the infectivity of all the examined primary
HIV-1 isolates. Importantly, these peptides also facilitated the
transmission of HIV-1BaL from PBMCs to CEMx174 5.25M7 cells
(Fig. 3E). These results suggested that EPs effectively enhanced
the infectivity of both cell-free and cell-associated HIV-1 of differ-
ent subtypes and co-receptor tropisms.
3.3. Mechanism by which EPs enhance HIV-1 infection
Using a virus removal assay, we found that EPs enhanced HIV-1
infection only when the peptides were added to the cells either
before or at the same time as the virus attached to the cells. No
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peptides were added after the virus bound to the cells (Fig. 4A).
Therefore, EPs might target the virus entry process to boost virus
infection.
Next, we examined the mechanism of action by which EPs en-
hance HIV-1 infection. Using a virus pull-down assay as reported
previously [14], we found that the levels and infectivity of HIV-1
treated with EPs or SEVI in the pellets were much higher than
those of viruses treated with PBS (Fig. 4B and C). However, the
infectivity of the viruses treated with SEVI was signiﬁcantly lower
than the viruses treated with EPs, while the levels (p24 concentra-
tion) of the viruses bound to SEVI and EPs were in a similar range.
These results suggested that although these peptides exhibit a sim-
ilar potency to bind to HIV-1, SEVI was not as efﬁcient as EPs in
enhancing viral infection, possibly because these peptides form
amyloid ﬁbrils exhibiting different properties.Next, we sought to determine whether EPs could also bind to
target cells and enhance HIV-1 infection. When the peptides were
ﬁrst incubated with TZM-bl cells, we detected increased virus
binding and subsequent higher viral infectivity (Fig. 4D and E).
3.4. EPs suppress the anti-HIV-1 activity of ARVs
The EP-induced increase in HIV-1 infection antagonised the
anti-viral activity of T-20 [1]. Thus, we investigated whether EPs
could also counteract the inhibitory effect of current clinically
available ARVs. We evaluated the effect of EP2 on the antiviral
activity of four classes of ARVs against infection using two labora-
tory-adapted HIV-1 strains, IIIB (subtype B, X4) and BaL (subtype B,
R5). Surprisingly, we found that all of the examined ARVs exhibited
reduced anti-HIV-1 activity in the presence of 2 lM EP2 (Supple-
mentary Table S1). This low concentration of EP2 caused a general
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S. Tan et al. / FEBS Letters 588 (2014) 1515–1522 1519decrease in the in vitro effectiveness (i.e., an increase in the IC50 va-
lue) of the ARVs from approximately 2–15 fold. EP2 showed less
potency to enhance HIV-1 infection, it could be concluded that
EP1 and EP3 displayed stronger ability to antagonise the antiviral
activities of ARVs.
3.5. EGCG antagonises the EP2-mediated enhancement of HIV-1
infection by inhibiting the formation of amyloid ﬁbrils
We examined whether EGCG, a common amyloid ﬁbril inhibitor
and breaker, could exert any inﬂuence on EPs. To be consistence
with the above result, we continued to use EP2 as a representative
EP in this study.We incubated freshly dissolved EP2with EGCG, and
the formation of the b-sheet structures was monitored. The freshly
dissolved peptide could readily bind to ThT, implying a spontane-ous process of ﬁbril formation (Fig. 5A). During the incubation per-
iod of EP2 and EGCG, the ThT ﬂuorescence intensity decreased in
time- and dose-dependent manners, while the signals slightly in-
creased during incubation of EP2 alone (Fig. 5A). Next, we exposed
preformed EP2 ﬁbrils to various concentrations of EGCG and mon-
itored the degradation of the ﬁbrillar structures over time via ThT
staining. The preformed EP2 amyloid ﬁbrils (550 lM) were highly
stable in PBS for a period of 72 h. In contrast, the preformed amyloid
ﬁbrils were clearly degraded in the presence of EGCG (Fig. 5B).
Based on transmission electron microscopy, large EP2 ﬁbril aggre-
gates (275 lM) disappeared after the addition of EGCG (1375 lM)
during the 48-h incubation period (Supplementary Fig. S1), while
the EGCG control displayed no ﬁbril structures, as expected.
Next, we investigated whether EGCG could counteract the EP2-
mediated enhancement of HIV-1 infection. EP2 alone exhibited a
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1520 S. Tan et al. / FEBS Letters 588 (2014) 1515–1522potent enhancement of HIV-1 infectivity, while EGCG counteracted
the EP2-mediated increase in HIV-1 infectivity in a dose-depen-
dent manner. At a concentration approximately 10-fold higher
than that of EP2, EGCG could completely abrogate EP2-mediated
enhancement of HIV-1 infectivity (Fig. 5C). EGCG could also effec-
tively rescue the EP2-weakened antiviral activities of the ARVs
(Supplementary Table S2).
4. Discussion
In this study, we found that EPs derived from the HIV-1 gp120
co-receptor binding site could greatly enhance HIV-1 infectivity(Fig. 1). These peptides form amyloid ﬁbrils, as determined via
ThT staining assay, Congo red assay and electron microscopic anal-
ysis (Fig. 2A, B and C). EPs could substantially enhance the infectiv-
ity of both cell-free and cell-associated HIV-1 of various subtypes
and coreceptor tropisms (Fig. 3). Notably, EPs self-assembled and
displayed an ability to immediately form amyloid ﬁbrils. As soon
as the peptide was dissolved, it could readily bind to amyloid ﬁ-
bril-speciﬁc dyes, ThT (Fig. 5A), implying a spontaneous process
of b-sheet formation.
In mechanistic studies, we demonstrated that EPs exhibited a
strong potency to bind to HIV-1 and target cells, leading to a
remarkable increase in HIV-1 infectivity (Fig. 4). EPs enhanced
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loid ﬁbrils appear to share a common feature to enhance HIV-1
infectivity by targeting the viral entry process. This feature may
be explained by their aggregated structures, which could serve as
an arm to connect the virus to the target cells. In addition, the
properties of amyloid ﬁbrils, such as their cationic property [14],
may act like a hand to grab the viruses and cells tightly, thus fulﬁll-
ing the process of directing the viruses to the cells. However, as
found in our study, different amyloid ﬁbrils exhibited different
potencies of HIV-1 infectivity enhancement. This result may be
due to differences in ﬁbril structure, ﬂexibility, density, and bind-
ing properties. Aromatic residues, such as tryptophan in EPs, mightprovide sufﬁcient hydrophobicity to facilitate interactions between
EPs and the membrane [20,21]. Thus, EPs could bind to viruses and
enrich the binding of viruses to the cellular membrane surface to
enhance viral infection. In addition to cell-free virions, amyloid ﬁ-
brils might attract neighbouring HIV-1-infected cells to uninfected
target cells, leading to facilitated infection of the newly budding
viral particles [22].
It has been reported that the anti-HIV-1 activity of some ARV-
based microbicides was impaired in the presence of certain HIV-
1 infectivity-enhancing factors, such as SEVI and semen [18,23].
Our result suggests that the antiviral efﬁcacy of ARVs become
signiﬁcantly decreased in the presence of EPs (Supplementary
Table S1). For example, the addition of 2 lM EP2 to the virus
resulted in an increase in the IC50 values, ranging from 1.9 to
15.9-fold, of all the examined ARVs.
EGCG, an effective antioxidant and anti-infective agent, was
reported to inhibit amyloid ﬁbril formation and to disrupt
preformed amyloid ﬁbrils derived from various proteins
[10,11,24–26]. We found that EGCG also effectively inhibited
amyloid ﬁbril formation and disrupted the preformed ﬁbrils com-
posed of EP2 (Fig. 5A and B), thus counteracting the EP2-mediated
enhancement of HIV-1 infectivity (Fig. 5C).
Free gp120 exists in vivo [27] and it is subjected to many
degrading factors in vivo, including lysosomal or ubiquitin-medi-
ated intracellular degradation [28,29], and catalytic antibodies
[30–32]. Therefore, gp120 protein and peptide products are de-
tected in the serum and tissue in HIV-1/AIDS patients [33–35].
Fragments of EP2 have been reported to be present in hepatocyte
culture medium exposed to gp120, implying the physiological
presence of EPs in vivo. One limitation of our study is the lack of
a description of the physiological signiﬁcance of EPs. Both the exis-
tence of EPs in vivo and their biological function warrant further
investigation. EPs are virus-derived amyloid ﬁbrils, which are dis-
tinct from semen-derived amyloid ﬁbrils in that EPs self-assemble
and display a higher potency to enhance viral infectivity. These
properties warrant the potential biological applications of these
amyloid ﬁbrils. For example, EP may be used to promote the retro-
viral gene transfer. It has been reported that SEVI could be applied
to promote retroviral gene transfer [36]. Since EPs display higher
potency than SEVI to enhance retroviral infection, EPs might be
more effective in promoting retroviral gene transfer.Acknowledgements
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